Peptide record

TPDB91340

TAT-GFP TAT-LL37-VHHm3F TAT-VHHm3F Antibacterial Anticancer Antifungal Blood-Brain Barrier Cell-penetrating Peptides Toxicity Tumor-homing Peptides modified_plain modified
9 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91340
TAT-GFP TAT-LL37-VHHm3F TAT-VHHm3F
Antibacterial Anticancer Antifungal Blood-Brain Barrier Cell-penetrating Peptides Toxicity Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF CAFPdb dbAMP BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP TumorHoPe2.0
modified_plain
Yes
A 9-aa modified multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, AntiCP 2.0, and other sources, with an available 3D structural model.
Chemical: DiR labelled EVs
Sequence
RKKRRQRRR
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
9 reviewed residue count
Free Activity
DiR labelled EVs Activity
L Activity
Cationic Activity
Linear Activity
Free Activity
N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CS)C(=O)O N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O Activity
Evidence Records 3 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

Human Caco-2 Cells And Murine L929 Cells

Assay & Model

Adult C57BL/6 normal mice
Adult C57BL/6 normal mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
Green fluorescent protein (GFP)
TAT-GFP dose of 15 mg/kg in mice resulted in GFP primarily accumulating in colon after 4 h
In vitro and in vivo
CCCSSHHHHHHHHHHHHHHHHHHHSSCC
Evidence 2 Activity

Activity

Cell-penetrating Peptides

Target

Human Caco-2 Cells And Murine L929 Cells

Assay & Model

Adult C57BL/6 normal mice
Adult C57BL/6 normal mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
Anti‐tumour necrosis factor‐α (TNF‐α) nanobody (VHHm3F)
76.1% of EV were FITC-positive after incubation of FAM-labelled TAT-VHHm3F
In vitro and in vivo
CCGGGTSCC
Evidence 3 Activity

Activity

Cell-penetrating Peptides

Target

Human Caco-2 Cells

Assay & Model

Adult C57BL/6 normal mice
Adult C57BL/6 normal mice

Source & Reference

CPPsite3.0
CPPsite3

Other

Natural residues Linear L Cationic
Protein derived
VHH and an antimicrobial peptide LL37
87% of EV were FITC-positive when FAM-labelled TAT-LL37-VHHm3F was incubated with EV
In vitro and in vivo
CCGGGTSCC
Additional Detail Fields 1 fields
CCCSSHHHHHHHHHHHHHHHHHHHSSCC CCGGGTSCC